查詢結果分析
相關文獻
- Biochemotherapy with Carmustine, Cisplatin, Dacarbazine, Tamoxifen and Low-dose Interleukin-2 for Patients with Metastatic Malignant Melanoma
- Cervical Lymph Node Metastasis from Melanoma of an Unknown Primary Site--Case Report
- 鼻腔及副鼻竇之惡性黑色素腫瘤
- 口腔黏膜的惡性黑色素瘤--病例報告
- Malignant Melanoma of the Anorectum
- Malignant Melanoma Presenting as an Endobronchial Pulmonary Mass--A Case Report and Literature Review
- Cutaneous Metastatic Breast Carcinoma Mimicking Malignant Melanoma
- Nevus of Ota Associated with Ocular Malignant Melanoma
- 左上顎之惡性黑色素瘤
- 惡性黑色素瘤治療之近況
第1筆 /總和 1 筆
/ 1 筆
頁籤選單縮合
題 名 | Biochemotherapy with Carmustine, Cisplatin, Dacarbazine, Tamoxifen and Low-dose Interleukin-2 for Patients with Metastatic Malignant Melanoma=以低劑量之介白素-2對晚期惡性黑色素瘤的生物化學治療 |
---|---|
作 者 | 蘇柏榮; 陳仁熙; 廖宗琦; 張獻崑; 王宏銘; 楊再勝; 林永昌; 廖繼鼎; 楊馨怡; 葉光揚; 侯明模; 張乃仁; 王正旭; 張文震; | 書刊名 | 長庚醫誌 |
卷 期 | 34:5 2011.09-10[民100.09-10] |
頁 次 | 頁478-486 |
分類號 | 415.78 |
關鍵詞 | 惡性黑色素瘤; 卡氮芥; 順鉑; 氨烯咪胺; 他莫昔芬; 介白素-2; Malignant melanoma; Carmustine; Cisplatin; Dacarbazine; Tamoxifen; Interleukin-2; |
語 文 | 英文(English) |
英文摘要 | Background: The toxicity and efficacy of biochemotherapy with low-dose interleukin-2 for patients with metastatic malignant melanoma (MM) were studied. Method: Metastatic chemo-naïve MM patients were given biochemotherapy (BCDT regimen) with carmustine (BCNU), cisplatin (CDDP), dacarbazine (DTIC), and tamoxifen and interleukin-2 (IL-2) 18 Million International Units in divided doses by subcutaneous injection three times a week for four weeks. BCDT consisted of BCNU (150 mg/m2, day l every 8 weeks), CDDP (25 mg/m2, days l-3 every 4 weeks), DTIC (220 mg/m2, days 1-3 every 4 weeks) and tamoxifen 10 mg twice a day. Treatment was repeated for a total of 6 cycles, or until disease progression or unbearable toxicity. Results: From Nov 2001 to July 2005, 40 patients (20 men; 20 women) were enrolled. Their median age was 54 years (range 22-79 years). Subtypes of melanoma included 23 (57.5%) acral lentiginous, 11 (27.5%) nodular, 1 (2.5%) mucosal, and 5 (12.5%) others. Grade 3-4 toxicities included neutropenia (27.5%), anemia (45%), and thrombocytopenia (40%). Constitutional IL-2 toxicities included indurate injection site (57.5%), fever (60%), chills (55%), itchy skin (42.5%), bone pain (32.5%) and myalgia (45%). Grade 1-2 hypotension was noted in 12.5% of patients. Eosinophilia (range 5% to 71%) was evident in 72.5% of patients. The response rate was 32.5% including 5% with a complete response, 27.5% with a partial response, and 17.5% with stable disease. The median progression-free survival was 6.2 months (95% CI: 2.9~9.6 months). The median overall survival was 11.3 months (95% CI: 7.0~15.6 months). Five patients (12.5%) who presented with oligo-metastasis achieved five-year survivals. Conclusions: Our data demonstrated that low-dose IL-2 plus BCDT is tolerable. A durable response and long-term survival can be achieved in a small subgroup of patients. |
本系統中英文摘要資訊取自各篇刊載內容。